Viral hepatitis in elderly haemodialysis patients: Current prevention and management strategies

Drugs and Aging

Volumn 25, Issue 10, 2008, Pages 823-840

  Girndt, Matthias ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Adefovir, therapeutic use; Elderly; Entecavir, therapeutic use; Haemodialysis; Hepatitis B vaccine, therapeutic use; Hepatitis B, treatment; Hepatitis C, treatment; Interferon alpha, therapeutic use; Lamivudine, therapeutic use

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS VACCINE; INTERLEUKIN 2; LAMIVUDINE; LIVER ENZYME; PEGINTERFERON ALPHA; RIBAVIRIN;

AGED; AGING; ARTHRALGIA; BONE MARROW SUPPRESSION; CELL DIFFERENTIATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HEMODIALYSIS PATIENT; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; INFECTION PREVENTION; INFECTION RISK; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MENTAL DISEASE; MONOTHERAPY; MYOPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

AGED; HEALTH SERVICES FOR THE AGED; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; RENAL DIALYSIS;

EID: 52449115925     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825100-00002     Document Type: Review

References (122)

1. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005 Jun; 25 (3): 472-89
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 Feb; 45 (2): 507-39
3. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002 Jun 10; 19 (3): 1-46
4. McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007 May; 22 (5): 615-33
5. Dianzani F. Biological basis for the clinical use of interferon. Gut 1993; 34 (2 Suppl.): S74-6
6. Rostaing L, Modesto A, Baron E, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74 (3): 512-6
7. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993 Aug 15; 119 (4): 312-23
8. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989 Nov; 10 (5): 761-3
9. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006 Feb; 101 (2): 297-303
10. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 Oct 21; 341 (17): 1256-63
11. Kawaoka T, Suzuki F, Akuta N, et al. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol 2007 May; 42 (5): 395-401
12. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 Dec; 125 (6): 1714-22
13. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000 Apr; 46 (4): 562-8
14. Rudin D, Shah SM, Kiss A, et al. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 2007 Nov; 27 (9): 1185-93
15. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 Feb 27; 348 (9): 808-16
16. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 Mar 9; 354 (10): 1001-10
17. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 Mar 9; 354 (10): 1011-20
18. Song BC, Suh DJ, Lee HC, et al. Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea? J Clin Gastroenterol 2004 Feb; 38 (2): 124-9
19. Manns MP, McHutchison JG, Gordon SC, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 Sep 22; 358 (9286): 958-65
20. Fried MW, Shiffman ML, Reddy KR, et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26; 347 (13): 975-82
21. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peg-interferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 Mar 2; 140 (5): 346-55
22. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995 Oct; 22 (4 Pt 1): 1050-6
23. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995 Oct; 22 (4 Pt 1): 1326-9
24. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 Apr; 39 (4): 1147-71
25. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50 (1): 16-23
26. Thabut D, Le CS, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006 Jun; 101 (6): 1260-7
27. Bresci G, Del CL, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993 Aug; 41 (8): 857-62
28. Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995 May; 10 (3): 246-9
29. Honda T, Katano Y, Urano F, et al. Efficacy of ribavirin plus interferon-alpha in patients aged ≥60 years with chronic hepatitis C. J Gastroenterol Hepatol 2007 Jul; 22 (7): 989-95
30. Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc 2006 Mar; 54 (3): 549-50
31. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fcg receptors in end-stage renal disease. N Engl J Med 1990; 322: 717-22
32. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005 Apr; 67 (4): 1216-33
33. Girndt M, Köhler H, Schiedhelm-Weick E, et al. T-cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int 1993; 44: 359-65
34. London WT, DiFiglia M, Sutnick AI, et al. An epidemic of hepatitis in a chronic hemodialysis unit. N Engl J Med 1969; 281: 571-8
35. Crosnier J, Jungers P, Couroucé AM, et al. Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French hemodialysis units: II. Hemodialysis patients. Lancet 1981; I: 797-800
36. Meuer SC, Hauer M, Kurz P, et al. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired immune responses. J Clin Invest 1987; 80: 743-9
37. Meuer SC, Dumann H, Meyer zum Büschenfelde KH, et al. Low dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; I: 15-8
38. Liu Y, Janeway CA. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci U S A 1992; 89: 3845-9
39. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 1998; 165: 231-47
40. Schweitzer AN, Sharpe AH. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol 1998; 161: 2762-71
41. Beaman M, Michael J, MacLennan IC, et al. T-cell-independent and T-cell-dependent antibody responses in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 216-21
42. Girndt M, Sester M, Sester U, et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001 Apr; 59 (4): 1382-9
43. Girndt M, Sester U, Kaul H, et al. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single cell level. J Am Soc Nephrol 1998; 9: 1689-96
44. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-911
45. Girndt M, Köhler H, Schiedhelm Weick E, et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559-65
46. Sester U, Sester M, Hauk M, et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1217-23
47. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997 Jun; 18 (6): 263-6
48. Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005 Dec; 46 (6): 997-1011
49. Pillion G, Chiesa M, Maisin A, et al. Immunogenicity of hepatitis B vaccine (HEVAC B) in children with advanced renal failure. Pediatr Nephrol 1990; 4: 627-9
50. Gershon AA. Immunizations for pediatric transplant patients. Kidney Int 1993; 44 Suppl. 43: S87-90
51. Flynn JT, Frisch K, Kershaw DB, et al. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999; 15: 269-72
52. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000 Aug; 31 (2): 578-85
53. Bernstein E, Kaye D, Abrutyn E, et al. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999 Jan; 17 (1): 82-94
54. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 2001 May; 8 (3): 131-6
55. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Ann Rev Med 2000; 51: 245-70
56. Mountz JD, Wu J, Zhou T, et al. Cell death and longevity: implications of Fas-mediated apoptosis in T-cell senescence. Immunol Rev 1997 Dec; 160: 19-30
57. Schwab R, Szabo P, Manavalan JS, et al. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 1997 May 1; 158 (9): 4493-9
58. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol 2002 Oct; 58 (4): 301-4
59. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004 Nov 15; 20 (10): 1053-62
60. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993 Dec; 44 (6): 1322-6
61. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The UCL Collaborative Group. Kidney Int 1998 Apr; 53 (4): 1022-5
62. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001 Jul 5; 345 (1): 41-52
63. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981 Mar 7; I (8219): 550-1
64. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep 2001; 50 (RR-5): 1-43
65. The EBPG Expert Group on Haemodialysis. European best practice guidelines for haemodialysis. Nephrol Dial Transplant 2002; 17 Suppl. 7: 72-87
66. Najem GR, Louria DB, Thind IS, et al. Control of hepatitis B infection: the role of surveillance and an isolation hemodialysis center. JAMA 1981 Jan 9; 245 (2): 153-7
67. Tokars JI, Arduino MJ, Alter MJ. Infection control in hemodialysis units. Infect Dis Clin North Am 2001 Sep; 15 (3): 797-812, viii
68. de Jong GM, de Bruin W, Verresen L, et al. High-flux membranes are not permeable to hepatitis B virus-DNA [letter]. Nephron 1992; 60 (3): 368
69. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a high-risk population in the United States. N Engl J Med 1980; 303: 833-41
70. Köhler H, Arnold WC, Renschin G, et al. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124-8
71. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72 (4): 536-43
72. Saab S, Brezina M, Gitnick G, et al. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 2001 Jul; 38 (1): 91-7
73. Mettang T, Schenk U, Thomas S, et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure: a preliminary study. Nephron 1996; 72 (2): 192-6
74. Fabrizi F, Andrulli S, Bacchini G, et al. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997 Jun; 12 (6): 1204-11
75. Vlassopoulos D, Arvanitis D, Lilis D, et al. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Ren Fail 1997 May; 19 (3): 455-60
76. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000 Nov; 36 (5): 976-82
77. Fabrizi F, Lunghi G, Alongi G, et al. Biological dynamics of hepatitis B virus load in dialysis population. Am J Kidney Dis 2003 Jun; 41 (6): 1278-85
78. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 Jan 4; 295 (1): 65-73
79. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994 Apr; 106 (4): 1000-5
80. Josselson J, Kyser BA, Weir MR, et al. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987 Jun; 9 (6): 456-61
81. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996 Jul 27; 62 (2): 297-9
82. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999 Jan; 29 (1): 257-63
83. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8
84. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001 May; 16 (5): 1017-23
85. Bohjanen PR, Johnson MD, Szczech LA, et al. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother 2002 Aug; 46 (8): 2387-92
86. Ben Ari Z, Broida E, Kittai Y, et al. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol 2000 Dec; 95 (12): 3579-83
87. Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, et al. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003 Jul; 37 (1): 64-7
88. Lapinski TW, Flisiak R, Jaroszewicz J, et al. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005 Jan 21; 11 (3): 400-2
89. Garcia A, Mazuecos A, Gonzalez P, et al. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc 2005 Apr; 37 (3): 1462-3
90. Fontaine H, Vallet-Pichard A, Chaix ML, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005 Oct 27; 80 (8): 1086-92
91. European Medicines Agency (EMEA). Hepsera (adefovir dipivoxil): European public assessment report [online]. Available from URL: http://www.emea.europa. eu/humandocs/Humans/EPAR/hepsera/hepsera.htm [Accessed 2007 Jan 31]
92. European Medicines Agency (EMEA). Baraclude (entecavir): European public assessment report [online]. Available from URL: http://www.emea.europa.eu/ humandocs/Humans/EPAR/baraclude/baraclude.htm [Accessed 2007 Aug 22]
93. Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007 Feb; 112 (3): 141-55
94. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J Gastroenterol 2004 Aug 1; 10 (15): 2209-12
95. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999 Dec; 94 (12): 3576-82
96. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002 Jan; 17 (1): 129-33
97. Lau JY, Davis GL, Brunson ME, et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993 Nov; 18 (5): 1027-31
98. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994 May; 45 (5): 1507-9
99. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995 May; 47 (5): 1412-8
100. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients: pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999 Nov; 14 (11): 2704-9
101. Huraib S, Tanimu D, Romeh SA, et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999 Jul; 34 (1): 55-60
102. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997 Dec; 176 (6): 1614-7
103. Okuda K, Hayashi H, Yokozeki K, et al. Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series. J Gastroenterol Hepatol 1995 Sep; 10 (5): 616-20
104. Raptopoulou-Gigi M, Spaia S, Garifallos A, et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995 Oct; 10 (10): 1834-7
105. Chan TM, Wu PC, Lau JY, et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997 Jul; 12 (7): 1414-9
106. Fernandez JL, Rendo P, del Pino N, et al. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels: Nephrologists' Group for the Study of HCV infection. J Viral Hepat 1997 Mar; 4 (2): 113-9
107. Hanrotel C, Toupance O, Lavaud S, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001 Jun; 88 (2): 120-6
108. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001 Apr; 96 (4): 1170-7
109. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001 Mar; 55 (3): 220-6
110. Rocha CM, Perez RM, Ferreira AP, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006 Apr; 26 (3): 305-10
111. Grgurevic I, Vince A, Buljevac M, et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract 2006; 103 (1): c8-11
112. Covic A, Maftei ID, Mardare NG, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006 Nov; 19 (6): 794-801
113. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006 Mar; 21 (3): 575-80
114. Sporea I, Popescu A, Sirli R, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006 Jul 14; 12 (26): 4191-4
115. Russo MW, Ghalib R, Sigal S, et al. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006 Feb; 21 (2): 437-43
116. Russmann S, Grattagliano I, Portincasa P, et al. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13 (27): 3351-7
117. Pol S, Vallet-Pichard A, Fontaine H, et al. HCV infection and hemodialysis. Semin Nephrol 2002 Jul; 22 (4): 331-9
118. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001 Jan; 16 (1): 193-5
119. Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection: a pilot study. J Viral Hepat 2001 Jul; 8 (4): 287-92
120. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006 May; 13 (5): 316-21
121. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 Oct 31; 352 (9138): 1426-32
122. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C: International Hepatitis Interventional Therapy Group. N Engl J Med 1998 Nov 19; 339 (21): 1493-9